UK Clinical Investigations for Medical Devices Reach Record Highs

The United Kingdom has seen a significant surge in the testing of new medical devices, with clinical investigations reaching their highest level on record in 2025. Data released by the Medicines and Healthcare products Regulatory Agency (MHRA) indicates a 17 percent increase in approved clinical investigations compared to the previous year. This growth suggests that more companies are selecting Great Britain as a primary location to test cutting-edge health technologies. The rise in activity is expected to provide patients with faster access to innovative diagnostic tools and treatment options. These developments span various fields, including artificial intelligence, neurotechnology, and advanced surgical robotics. The MHRA has maintained a strong performance record, meeting all statutory deadlines for clinical investigation applications since September 2023. In 2025, the average approval time for these investigations was 51 days, reflecting a commitment to regulatory efficiency. This streamlined process is designed to help developers move promising concepts into real-world clinical settings more quickly. To support this momentum, the agency has expanded its specialist advice meetings for complex technologies. These sessions allow developers to engage with regulators early in the design process to ensure safety and compliance. The MHRA is also participating in a new partnership led by Newcastle University to update national guidance on neurotechnology research. This initiative aims to make the regulatory landscape clearer for clinicians and companies working on devices that interact with the nervous system. By reducing unnecessary barriers, the agency hopes to foster an environment where innovation can thrive without compromising patient safety. The focus remains on backing high-impact ideas that can lead to more precise treatments and earlier disease detection. As these technologies move through the pipeline, the UK continues to position itself as a central hub for global medical device development.